Skip to main content
Download PDF

Volume 9 Supplement 1

Proceedings of 18th Pediatric Rheumatology European Society (PReS) Congress

Auto-antibody testing for children on biologic therapies for rheumatological conditions: results of audit

Pediatric Rheumatology volume 9, Article number: P199 (2011) Cite this article

Background

Biologic agents may cause auto-antibody formation and drug induced lupus but no paediatric guidelines exist regarding monitoring of auto-antibodies. The UK Royal College of Nursing Guidance advises checking ANA and anti-dsDNA before starting biologic treatment and repeating anti-dsDNA if concerned.

The Alder Hey protocol tested an autoantibody profile (Table 1, 2) 3-6 monthly for data entry for the British Paediatric and Adolescent Rheumatology (BSPAR) Biologics and New Drugs Registry (BDNR) and children with day ward IV biologic administration often had automatic antibodies testing 4-6 weekly.

Table 1 Table 1
Full size table
Table 2 Table 2
Full size table

Aim

To analyse frequency of antibody positivity in rheumatology patients on biologics in order to estimate costs and to devise a rational protocol for test frequency.

Method

A retrospective audit of a 2 year period, August 2008 to July 2010. All patients on biologics were included with data on auto-antibodies collated using the hospital computer system.

Results

111 children were receiving biologic therapy and 2511 auto-antibodies were tested at a cost of over £26,000.

Conclusion

With the exception of ANA antibody, all other antibody tests were usually negative. Those that were positive tended to be non specific (ie. ANCA non-PR3 / MPO; ENA no specific specificity) and/or were negative on subsequent testing. The results did not alter patient care yet costs are significant. This audit would suggest that antibody tests are checked too frequently at Alder Hey Hospital. A new protocol in development is likely to recommend testing auto-antibodies annually in the absence of clinical signs / symptoms of lupus.

Author information

Affiliations

  1. Alder Hey Children’s NHS Foundation Trust, UK

    Julie Duncan, Jill Heath, Eileen Baildam, Gavin Cleary, Michael Beresford & Liza J McCann

Authors
  1. Julie Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jill Heath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eileen Baildam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gavin Cleary
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Beresford
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liza J McCann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie Duncan.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Duncan, J., Heath, J., Baildam, E. et al. Auto-antibody testing for children on biologic therapies for rheumatological conditions: results of audit. Pediatr Rheumatol 9, P199 (2011). https://doi.org/10.1186/1546-0096-9-S1-P199

Download citation

Keywords

  • Royal College
  • Biologic Therapy
  • Antibody Test
  • Drug Registry
  • Rational Protocol

Pediatric Rheumatology

ISSN: 1546-0096